En blogg där jag tar upp alternativ politik och radikala ekonomiska frågor som inte diskuteras varken i tidningarnas spalter eller vid kaffeborden. Jag startade bloggen i augusti 2007.
The other method is reverse genetics—assembling a new virus with sets of genes from the H5N1 and H3N2 viruses. Reverse genetics has already been used to create H5N1 candidate vaccines in several laboratories, according to Daigle. The National Institutes of Health (NIH) said recently it would soon launch a clinical trial of one of those vaccines.
Of the two methods, the co-infection approach was described as slower and more laborious, though closer to what happens in nature.
Hold it right there. Seven months later BiondVax, an Israeli company, developed a "quantum leap in technology" for influenza vaccines. The key players are Isaac Devash, Chairman, Ron Babecoff, Founder and CEO, and Ruth Arnon, Weizmann Institute of Science Professor.
1 kommentar:
http://twelfthbough.blogspot.com/2009/08/making-vaccine-keystone-of-any-effort.html
http://twelfthbough.blogspot.com/2009_04_01_archive.html
The other method is reverse genetics—assembling a new virus with sets of genes from the H5N1 and H3N2 viruses. Reverse genetics has already been used to create H5N1 candidate vaccines in several laboratories, according to Daigle. The National Institutes of Health (NIH) said recently it would soon launch a clinical trial of one of those vaccines.
Of the two methods, the co-infection approach was described as slower and more laborious, though closer to what happens in nature.
Hold it right there. Seven months later BiondVax, an Israeli company, developed a "quantum leap in technology" for influenza vaccines. The key players are Isaac Devash, Chairman, Ron Babecoff, Founder and CEO, and Ruth Arnon, Weizmann Institute of Science Professor.
Skicka en kommentar